Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mirikizumab Regulates Genes Involved in Ulcerative Colitis Disease Activity and Anti-TNF Resistance: Results From a Phase 2 Study

7 Mar 2023

Abstract excerpt

INTRODUCTION: Mirikizumab, a monoclonal antibody targeting the p19 subunit of interleukin (IL)-23, demonstrated efficacy and was well-tolerated in a phase 2 randomized clinical trial in patients with moderate-to-severe ulcerative colitis (UC) (NCT02589665). We explored gene expression changes in colonic tissue from study patients and their association with clinical outcomes. METHODS: Patients were randomized to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Dermatology and Skin Diseases
Share to Inflammatory Bowel Disease
Share to Psoriasis: Treatment and Pathogenesis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36881820
DOI: 10.14309/ctg.0000000000000578

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mirikizumab Regulates Genes Involved in Ulcerative Colitis Disease Activity and Anti-TNF Resistance: Results From a Phase 2 StudyPMID 36881820Read ↗

The Clinical Response of Upadacitinib and Risankizumab is Associated with Reduced Inflammatory Bowel Disease Anti-TNFα Inadequate Response MechanismsSemantic proximity Read ↗

Systems-level analysis of monocyte responses in inflammatory bowel disease identifies IL-10 and IL-1 cytokine networks that regulate IL-23Semantic proximity Read ↗

Mucosal gene expression of inflammatory cytokines as biomarkers for predicting treatment response in patients with inflammatory bowel diseaseSemantic proximity Read ↗

Ulcerative colitis immune cell landscapes and differentially expressed gene signatures determine novel regulators and predict clinical response to biologic therapySemantic proximity Read ↗

Decoding Cytokine Networks in Ulcerative Colitis to Identify Pathogenic Mechanisms and Therapeutic TargetsSemantic proximity Read ↗

Identification of gene signatures associated with ulcerative colitis and the association with immune infiltrates in colon cancerSemantic proximity Read ↗

Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis.Semantic proximity Read ↗

Discovery and validation of mucosal TNF expression combined with histological score - a biomarker for personalized treatment in ulcerative colitisSemantic proximity Read ↗

Interleukin-22 regulates neutrophil recruitment in ulcerative colitis and is associated with resistance to ustekinumab therapySemantic proximity Read ↗

A JAK-STAT-activated myeloid hub at ulceration sites underlies resistance to anti-TNF therapy in Crohn’s diseaseSemantic proximity Read ↗

Targeting the IL-23 Receptor Gene: A Promising Approach in Inflammatory Bowel Disease TreatmentSemantic proximity Read ↗

Insights into Therapeutic Response Prediction for Ustekinumab in Ulcerative Colitis Using an Ensemble Bioinformatics ApproachSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.